Table 3.
A summary among females of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing hepatitis B vaccine administration within the Vaccine Safety Datalink (VSD) database.
| Group examined | Number of females diagnosed with specific delays in development (%) | Number of females in the cohort | Relative risk (95% CI) | Attributable risk % (95% CI) | Population attributable risk % (95% CI) |
|---|---|---|---|---|---|
| Experiment VII | |||||
| 12.5 μg Organic mercury within the first mo | 261 (2.78) | 9122 | 1.207* (1.031–1.413) | 0.4765 (0.0682–0.885) | 7.247 (1.061–13.43) |
| 0 μg Organic mercury within the first mo | 356 (2.31) | 15,088 | |||
| Experiment VIII | |||||
| 25 μg Organic mercury within the first 2 mo | 261 (2.78) | 9134 | 1.207* (1.03–1.415) | 0.4773 (0.0678–0.887) | 7.376 (1.073–13.68) |
| 0 μg Organic mercury within the first 2 mo | 347 (2.30) | 14,735 | |||
| Experiment IX | |||||
| 37.5 μg Organic mercury within the first 6 mo | 198 (2.84) | 6779 | 1.982* (1.136–3.459) | 1.406 (0.541–2.271) | 46.5 (18.54–74.46) |
| 0 μg Organic mercury within the first 6 mo | 13 (1.43) | 895 | |||
CI = confidence interval.
*
p < 0.05.